Zobrazeno 1 - 10
of 438
pro vyhledávání: '"Kelvin K W, Chan"'
Autor:
Qi Guan, Suriya J. Aktar, Reka E. Pataky, Mariet Mathew Stephen, Maud Marques, Karen Gambaro, Kahina Rachedi, Katharina Forster, Samara Strub, David Stock, Louis de Léséleuc, Winson Y. Cheung, Stuart Peacock, Christie Farrer, Scott Gavura, Mina Tadrous, Robert C. Grant, Kelvin K. W. Chan
Publikováno v:
Current Oncology, Vol 31, Iss 6, Pp 3591-3602 (2024)
Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug’s safety profile in the real world remains uncertain. We conducted a cohort study to describe the patie
Externí odkaz:
https://doaj.org/article/7817f7dbf22f4c7abc1ea613261997ef
Autor:
Pam Takhar, Marc Geirnaert, Scott Gavura, Jaclyn Beca, Rebecca E. Mercer, Avram Denburg, Caroline Muñoz, Mina Tadrous, Ambica Parmar, Francois Dionne, Darryl Boehm, Carole Chambers, Erica Craig, Maureen Trudeau, Matthew C. Cheung, Joanne Houlihan, Valerie McDonald, Petros Pechlivanoglou, Marianne Taylor, Eric Wasylenko, Wiesława Dominika Wranik, Kelvin K. W. Chan
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1876-1898 (2024)
Multi-criteria decision analysis (MCDA) is a value assessment tool designed to help support complex decision-making by incorporating multiple factors and perspectives in a transparent, structured approach. We developed an MCDA rating tool, consisting
Externí odkaz:
https://doaj.org/article/8cbdb12baeaa4a1eacebc73b853c3a3f
Autor:
Caroline Muñoz, Xiaochen Tai, Jessica Arias, Andrea Eisen, Munaza Chaudhry, Scott Gavura, Kelvin K. W. Chan
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1633-1644 (2024)
Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Her
Externí odkaz:
https://doaj.org/article/d807639d5b19417a82cf897cac5c9fb4
Autor:
Caitlin S. Lees, Hsien Seow, Kelvin K. W. Chan, Anastasia Gayowsky, Shaila J. Merchant, Aynharan Sinnarajah
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1170-1182 (2024)
Indices of aggressive or supportive end-of-life (EOL) care are used to evaluate health services quality. Disparities according to sex were previously described, with studies showing that male sex is associated with aggressive EOL care. This is a seco
Externí odkaz:
https://doaj.org/article/cda488cd491d4eb78ed0a0a10d5054ec
Autor:
Joachim Worthington, Zhuolu Sun, Rui Fu, Jie-Bin Lew, Kelvin K. W. Chan, Qing Li, Antoine Eskander, Harriet Hui, Kirstie McLoughlin, Michael Caruana, Stuart Peacock, Jean Hai Ein Yong, Karen Canfell, Eleonora Feletto, Talía Malagón
Publikováno v:
PLoS ONE, Vol 19, Iss 4 (2024)
Externí odkaz:
https://doaj.org/article/29d122c7f61c44c9a96f81ddd6df7eb3
Autor:
Yue (Jennifer) Du, Rui Fu, Justin T. Levinsky, Pabiththa Kamalraj, Kelvin K. W. Chan, Ambica Parmar, Antoine Eskander, Martin Smoragiewicz
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 8928-8935 (2023)
Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and e
Externí odkaz:
https://doaj.org/article/1a7be7b7504d494daa77cb02299d0e67
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Historically, a priori power and sample size calculations have not been routinely performed cost-effectiveness analyses (CEA), partly because the absence of published cost and effectiveness correlation and variance data, which are
Externí odkaz:
https://doaj.org/article/34bc2463e93843559d55ea2323c25eee
Autor:
Rui Fu, Rinku Sutradhar, Qing Li, Pabiththa Kamalraj, Anna Dare, Timothy P. Hanna, Kelvin K. W. Chan, Jonathan C. Irish, Natalie Coburn, Julie Hallet, Simron Singh, Ambica Parmar, Craig C. Earle, Lauren Lapointe‐Shaw, Monika K. Krzyzanowska, Alexander V. Louie, Alyson Mahar, David R. Urbach, Daniel I. McIsaac, Danny Enepekides, David Gomez, Nicole J. Look Hong, Jill Tinmouth, Antoine Eskander
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11849-11859 (2023)
Abstract Background Little is known about the association between the COVID‐19 pandemic and early survival among newly diagnosed cancer patients. Methods This retrospective population‐based cohort study used linked administrative datasets from On
Externí odkaz:
https://doaj.org/article/88d1d600525e42fa9ed5252b53c0be68
Autor:
Brandon Lu, Wei Fang Dai, Ruth Croxford, Wanrudee Isaranuwatchai, Jaclyn Beca, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11451-11461 (2023)
Abstract Background The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with init
Externí odkaz:
https://doaj.org/article/f0604d85f42d4d3396b6316504533bac
Autor:
Ambica Parmar, Wei Fang Dai, Francois Dionne, Marc Geirnaert, Avram Denburg, Tarry Ahuja, Jaclyn Beca, Sylvie Bouchard, Carole Chambers, Melissa J. Hunt, Don Husereau, Elena Lungu, Valerie McDonald, Rebecca E. Mercer, Gunita Mitera, Caroline Muñoz, Rohini Naipaul, Stuart Peacock, Tanya Potashnik, Mina Tadrous, Pam Takhar, Marianne Taylor, Maureen Trudeau, Danica Wasney, Scott Gavura, Kelvin K. W. Chan
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 3776-3786 (2023)
The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration developed an MCDA rating tool to assess and prioritize potential post-market real-world evidence (RWE) questions/uncertainties emerging from public drug funding dec
Externí odkaz:
https://doaj.org/article/4fb575f2c14545e7887f622958f92f21